SELLAS Shares Flat on Test Results

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) found its shares holding their own Monday. The late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, provided a clinical update on the ongoing Phase 1 dose-escalating clinical trial of GFH009, its novel and highly selective CDK9 inhibitor, in advanced relapsed and refractory lymphoma and acute myeloid leukemia (AML).

In the AML group, patients treated at the 22.5 mg dose level experienced no dose limiting toxicities, including no grade 3/4 neutropenias (an abnormally low count of neutrophils, a type of white blood cell). The AML group has entered the last planned dose level of 30 mg.

In the lymphoma group, the 15 mg dose level cohort has completed enrollment. Safety assessments for this cohort are currently underway. In the previous 9 mg dose level cohort, one patient, with peripheral T-cell lymphoma, an aggressive type of lymphoma that develops from mature-stage T-cells and natural killer (NK) cells who was refractory to three prior lines of therapy, demonstrated a partial response as seen on a computerized tomography scan.

Said Company Spokesman Dragan Cicic, “The clinical process for safety is to determine the highest dose level patients can tolerate without experiencing adverse events or side effects.

“Not only does GFH009 appear to be safe at the dose levels studied to date, but we have also observed efficacy in lower dose levels. These results are encouraging as we continue to increase dose levels and assess accordingly.”

SLS shares acquired one cent to $2.37.